Ionis Pharmaceuticals, Inc. (0JDI.L) LSE

72.90

-2.25(-2.99%)

Updated at June 02 06:55PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Brett Monia	Founder, Chief Executive Officer & Director	3.47M	1961
C. Frank Bennett	Executive Vice President & Chief Scientific Officer	651,639	1957
Kyle Jenne	Executive Vice President & Chief Global Product Strategy Officer	804,966	1977
Patrick R. O'Neil	Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary	1.21M	1974
Eric E. Swayze	Executive Vice President of Research	1.23M	1966
Brian Birchler	Executive Vice President of Corporate & Development Operations	1.24M	1966
Richard S. Geary	Strategic Consultant	1.33M	1958
Elizabeth L. Hougen	Executive Vice President of Finance & Chief Financial Officer	1.6M	1962
Charles G. Asare	VP & Head of Drug Safety	0	N/A
Roger Lane	Senior Vice President of Clinical Development	0	N/A
Rachel Carnes	Senior Vice President of Global Product Strategy	0	N/A
Hala Mirza	Senior Vice President of Corporate Affairs & Patient Advocacy	0	N/A
Tracy Berns	Senior Vice President and Chief Compliance & Quality Assurance Officer	0	N/A
Sujit K. Basu	Vice President & Head of Pharmaceutical Development	0	N/A
Darren Gonzales	Chief Accounting Officer & Senior Vice President	0	N/A
D. Wade Walke	Senior Vice President of Investor Relations	0	N/A
Jonathan J. Birchall	Senior VP & Chief Commercial Officer	0	1970
Cliff Ford	Senior VP of Intellectual Property	0	N/A
Eugene Schneider	Executive Vice President, Chief Clinical Development & Operations Officer	0	1973

Name

Title

Pay

Year Born

Brett Monia

Founder, Chief Executive Officer & Director

3.47M

1961

C. Frank Bennett

Executive Vice President & Chief Scientific Officer

651,639

1957

Kyle Jenne

Executive Vice President & Chief Global Product Strategy Officer

804,966

1977

Patrick R. O'Neil

Executive Vice President, Chief Legal Officer, General Counsel & Corporate Secretary

1.21M

1974

Eric E. Swayze

Executive Vice President of Research

1.23M

1966

Brian Birchler

Executive Vice President of Corporate & Development Operations

1.24M

1966

Richard S. Geary

Strategic Consultant

1.33M

1958

Elizabeth L. Hougen

Executive Vice President of Finance & Chief Financial Officer

1.6M

1962

Charles G. Asare

VP & Head of Drug Safety

N/A

Roger Lane

Senior Vice President of Clinical Development

N/A

Rachel Carnes

Senior Vice President of Global Product Strategy

N/A

Hala Mirza

Senior Vice President of Corporate Affairs & Patient Advocacy

N/A

Tracy Berns

Senior Vice President and Chief Compliance & Quality Assurance Officer

N/A

Sujit K. Basu

Vice President & Head of Pharmaceutical Development

N/A

Darren Gonzales

Chief Accounting Officer & Senior Vice President

N/A

D. Wade Walke

Senior Vice President of Investor Relations

N/A

Jonathan J. Birchall

Senior VP & Chief Commercial Officer

1970

Cliff Ford

Senior VP of Intellectual Property

N/A

Eugene Schneider

Executive Vice President, Chief Clinical Development & Operations Officer

1973

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.